Submitted by Dr. Gary G. Kohls MD
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
By Maria Panagioti, et al – July 17, 2019 (Excerpted article: 480 words)
Full article, including author affiliations and references at: https://www.bmj.com/content/366/bmj.l4185
Objective
To systematically quantify the prevalence, severity, and nature of preventable patient harm across a range of medical settings globally.
Introduction
Patient harm during healthcare is a leading cause of morbidity and mortality internationally.
The World Health Organization defines patient harm as “an incident that results in harm to a patient such as impairment of structure or function of the body and/or any deleterious effect arising therefrom or associated with plans or actions taken during the provision of healthcare, rather than an underlying disease or injury, and may be physical, social or psychological (eg, disease, injury, suffering, disability and death).”
The health burden and patient experiencing healthcare-related patient harm has been reported to be comparable to chronic diseases such as multiple sclerosis and cervical cancer in developed countries, and tuberculosis and malaria in developing countries.
Harmful patient incidents are a major financial burden for healthcare systems across the globe.
It is estimated that 10-15% of healthcare expenditures are consumed by the direct sequelae of healthcare-related patient harm.
Early detection and prevention of patient harm in healthcare is an international policy priority.
In principle, zero harm would be the ideal goal. However, this goal is not feasible because some harms cannot be avoided in clinical practice.
For example, some adverse drug reactions which occur in the absence of any error in the prescription process and without the possibility of detection are less likely to be preventable.
Key sources of preventable patient harm could include the actions of healthcare professionals (errors of omission or commission), healthcare system failures, or involve a combination of errors made by individuals, system failures, and patient characteristics.
Key types of preventable harm were
- drug-related,
- diagnostic errors,
- medical procedure-related, and
- healthcare-acquired infections.
The excess length of hospital stays attributable to medical errors is estimated to be 2.4 million hospital days, which accounts for $9.3 billion excess charges in the US.
Another important finding is that preventable patient harm appears to be a serious concern in advanced medical specialties including intensive care and surgical units.
Patients treated in these specialties were more likely to experience preventable patient harm compared with patients treated in general hospitals. Surgical harm is a sizeable part of the overall in-hospital harm, but our estimates are higher than anticipated.
Conclusion
Our findings affirm that preventable patient harm is a serious problem across medical care settings. Priority areas are the mitigation of major sources of preventable patient harm (such as drug incidents) and greater focus on advanced medical specialties. It is equally imperative to build evidence across specialties such as primary care and psychiatry, vulnerable patient groups, future studies are critical for reducing patient harm in medical care settings.
______________________________________________________________________________
Appendix
Table of Annual Iatrogenic Deaths in The United States (235 words)
From: https://www.ourcivilisation.com/medicine/usamed/deaths.htm
(Deaths induced inadvertently by a physician or surgeon or by medical treatments or diagnostic procedures)
Adverse Drug Reactions 106,000 Deaths
Medical Error 98,000 Deaths
Bedsores 115,000 Deaths
Infection 88,000 Deaths
Malnutrition 108,800 Deaths
Outpatient Deaths 199,000 Deaths
Unnecessary Procedures 37,136 Deaths
Surgery-related 32,000 Deaths
TOTAL 783,936 Deaths
Annual Unnecessary Medical Events
The enumerating of unnecessary medical events is very important in our analysis. Any medical procedure that is invasive and not necessary must be considered as part of the larger iatrogenic picture.
Unfortunately, cause and effect go unmonitored. The figures on unnecessary events represent people (“patients”) who are thrust into a dangerous health care system. They are helpless victims.
Each one of these 16.4 million lives is being affected in a way that could have a fatal consequence. Simply entering a hospital could result in the following (out of 16.4 million people):
2.1% chance of a serious adverse drug reaction (186,000).
5% to 6% chance of acquiring a nosocomial [hospital] infection (489,500).
4% to 36% chance of having an iatrogenic injury in hospital (medical error and adverse drug reactions) (1.78 million).
17% chance of a procedure error (1.3 million).
All the statistics above represent a one-year time span. Imagine the numbers over a 10-year period. Working with the most conservative figures from our statistics we project the following 10-year death rates.
________________________________________________________________________________________________________________________________________________
Dr Gary Kohls is a retired rural family physician from Duluth, Minnesota who has written a weekly column for the Reader Weekly, Duluth’s alternative newsweekly magazine since his retirement in 2008. His column, titled Duty to Warn is re-published around the world.
Dr Kohls practiced holistic mental health care in Duluth for the last decade of his family practice career prior to his retirement in 2008, primarily helping patients who had become addicted to cocktails of psychiatric drugs to safely go through the complex withdrawal process. His column often deals with various unappreciated health issues, including those caused by Big Pharma’s over-drugging, Big Vaccine’s over-vaccinating, Big Medicine’s over-screening, over-diagnosing and over-treating agendas and Big Food’s malnourishing food industry. Those four sociopathic entities can combine to even more adversely affect the physical, mental, spiritual and economic health of the recipients of the vaccines, drugs, medical treatments and the eaters of the tasty and ubiquitous “FrankenFoods” – particularly when they are consumed in combinations, doses and potencies that have never been tested for safety or long-term effectiveness.
Dr Kohls’ Duty to Warn columns are archived at: http://duluthreader.com/search?search_term=Duty+to+Warn&p=2;
http://www.globalresearch.ca/author/gary-g-kohls;
http://freepress.org/geographic-scope/national; https://www.lewrockwell.com/author/gary-g-kohls/; and https://www.transcend.org/tms/search/?q=gary+kohls+articles
Dec 04, 2019 @ 13:42:49
Rosemary Gibson on Shortages of Lifesaving Drugs in U.S. Hospitals
Rosemary Gibson, author of China Rx: Exposing the Risks of America’s Dependence on China for Medicine, discussed the shortage of essential lifesaving drugs in U.S. hospitals.
https://www.c-span.org/video/?466812-5/washington-journal-rosemary-gibson-discusses-shortage-lifesaving-drugs-us-hospitals
LikeLike
Dec 04, 2019 @ 13:42:23
AAPS (Association of American Physicians and Surgeons)
Book Review: China Rx: Exposing the Risks of America’s Dependence on China for Medicine
by Rosemary Gibson and Janardan Prasad Singh,
“Without firing a missile or hacking the electric grid, China can take America down by disrupting access to essential drugs,” write the authors of this important book.
This book is a fine piece of investigative journalism that educates the reader about the genesis of China’s grip on our supply of medications. China is now the largest global supplier of the active ingredients and chemical building blocks needed to make many vitamins, and prescription and over-the-counter drugs. These include antibiotics, steroids, and cancer drugs.
Until the mid-1990s, the U.S., Europe, and Japan manufactured 90 percent of the global supply of key ingredients for the world’s medications. Now more than half of the 4,000 active ingredients needed to make a make a pharmaceutical depend on China.
Our weakness for bargains has created a monster. The authors note that hospitals and retail pharmacies have become “like the big box stores, stocked with made- in-China items.” China’s winning formula is for a company—with the help of the government—to undercut the price of drugs or components; the artificially low price forces other companies out of the market; then the company is free to manipulate the price and supply at will.
But the authors warn that “cheaper drugs required a cheaper way to make them.” A light was shined on China’s poor manufacturing practices of ingestibles in 2007 with the well-publicized dog and cat-food recall. More than 4,000 pets died from renal failure due to contamination with melamine, an industrial chemical used in plastics manufacture.
The outrage over this “economically motivated contamination” of pet food dissipated while in the next year a far less-publicized drug contamination took human lives. Although “manufactured” by an American company (Baxter Healthcare Corporation), heparin was made in China under substandard conditions and was sold to unwitting hospitals with tragic consequences. One-third of the batches of heparin from China were contaminated. The book fully explores the heparin debacle, telling how it happened and what our government has done about protecting us in the future.
From the start, the authors received robotic, scripted, unhelpful replies to the straightforward question: where was this drug made? Searching for the answer, the authors delve into the loopholes in treaties and Food and Drug Administration (FDA) regulations that have allowed shoddily manufactured drugs for human consumption to be used in the U.S. Moreover, politics was interjected. The Transparency in Drug Labeling Act was introduced in 2008 to force drug labels to disclose where the drug was produced, not merely the location of the parent company. The law went nowhere, and it appears that the power of the drug company lobbyists prevailed over safety. Did this signal to China that the U.S. could be influenced by special interests, sometimes to the detriment of its populace?
China’s latest Five-year Plan for National and Social Development includes entering (and cornering?) the market on medical devices. The centralization of global supply in China leaves the world vulnerable. Not only can they disrupt the supply chain and cause shortages but purposefully create shortages or adulterate drugs. Keep in mind, the active ingredient for ciprofloxin to treat anthrax is in China’s hands.
https://aapsonline.org/book-review-china-rx-exposing-the-risks-of-americas-dependence-on-china-for-medicine/
LikeLike